
Giuseppe Gritti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5645064/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nature Medicine, 2017, 23, 1416-1423.	30.7	196
2	lbrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica, 2015, 100, 77-86.	3.5	147
3	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. Journal of Clinical Oncology, 2019, 37, 3081-3089.	1.6	120
4	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology, 2020, 225, 152001.	1.9	120
5	Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities. Journal of Clinical Investigation, 2020, 130, 6021-6033.	8.2	102
6	Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nature Immunology, 2021, 22, 19-24.	14.5	101
7	Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood, 2021, 137, 637-645.	1.4	69
8	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. Journal of Clinical Oncology, 2016, 34, 4015-4022.	1.6	66
9	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia, 2014, 28, 642-648.	7.2	57
10	The lymphocyte to monocyte ratio improves the IPlâ€risk definition of diffuse large Bâ€cell lymphoma when rituximab is added to chemotherapy. American Journal of Hematology, 2013, 88, 1062-1067.	4.1	54
11	Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia, 2008, 22, 646-649.	7.2	47
12	SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Advances, 2020, 4, 1082-1092.	5.2	47
13	Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia, 2021, 35, 2710-2714.	7.2	42
14	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2020, 55, 393-399.	2.4	29
15	Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood, 2020, 136, 2628-2637.	1.4	29
16	Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood, 2022, 140, 25-37.	1.4	29
17	Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. Blood Advances, 2020, 4, 819-829.	5.2	28
18	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. Oncotarget, 2017, 8, 91703-91710.	1.8	21

GIUSEPPE GRITTI

#	Article	IF	CITATIONS
19	Circulating and progenitor endothelial cells are abnormal in patients with different types of von Willebrand disease and correlate with markers of angiogenesis. American Journal of Hematology, 2011, 86, 650-656.	4.1	20
20	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2019, 134, 2871-2871.	1.4	20
21	Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies. Journal of Clinical Oncology, 2021, 39, 444-455.	1.6	18
22	Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival. PLoS ONE, 2014, 9, e106745.	2.5	18
23	An Italian retrospective study on the routine clinical use of lowâ€dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. British Journal of Haematology, 2012, 156, 481-489.	2.5	17
24	Lowâ€dose alemtuzumabâ€associated immune thrombocytopenia in chronic lymphocytic leukemia. American Journal of Hematology, 2012, 87, 936-937.	4.1	14
25	Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 2767-2770.	1.3	14
26	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clinical Cancer Research, 2020, 26, 3546-3556.	7.0	13
27	Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood, 2020, 136, 45-47.	1.4	13
28	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R HOP14: A SAKK 38/07 trial postâ€hoc analysis. Hematological Oncology, 2022, 40, 12-22.	1.7	13
29	Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 424-429.	1.3	11
30	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica, 2017, 102, 1931-1935.	3.5	11
31	IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017010.	1.3	9
32	Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure. Respiratory Medicine, 2021, 185, 106477.	2.9	9
33	Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas. PLoS ONE, 2015, 10, e0121822.	2.5	9
34	Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. Oncotarget, 2018, 9, 9766-9775.	1.8	9
35	Chimeric antigen receptor T cells for gamma–delta T cell malignancies. Leukemia, 2022, 36, 577-579.	7.2	8
36	Successful management with intravenous immunoglobulins in alemtuzumab-induced acute inflammatory demyelinating neuropathy: clinical report of three patients. Immunopharmacology and Immunotoxicology, 2012, 34, 717-720.	2.4	7

GIUSEPPE GRITTI

#	Article	IF	CITATIONS
37	High interâ€follicular spatial coâ€localization of CD8+FOXP3+ with CD4+CD8+ cells predicts favorable outcome in follicular lymphoma. Hematological Oncology, 2022, 40, 541-553.	1.7	6
38	Donor-Derived CD19 CAR Cytokine Induced Killer (CIK) Cells Engineered with Sleeping Beauty Transposon for Relapsed B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood, 2019, 134, 200-200.	1.4	5
39	FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients. Hematological Oncology, 2018, 36, 299-306.	1.7	4
40	Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial. Blood, 2018, 132, 1691-1691.	1.4	4
41	Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab) Tj ETQq1 1 0.7843 Lymphoma. Blood, 2020, 136, 16-17.	814 rgBT / 1.4	Overlock 10 4
42	Role of Front-Line High Dose Therapy with Stem Cell Transplant in Peripheral T-Cell Lymphomas. A Single Center Experience Blood, 2012, 120, 2733-2733.	1.4	4
43	A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 5310-5310.	1.4	3
44	Life Expectancy in Follicular Lymphoma Is Mainly Determined By Response to First LINE Treatment: A LONG-TERM Survey on 597 Patients. Blood, 2015, 126, 3989-3989.	1.4	3
45	The Peripheral Blood Lymphocyte to Monocyte Ratio At Diagnosis Is a Potent Outcome Predictor in Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Long-Term Analysis On 973 Patients Receiving Chemotherapy with or without Rituximab. Blood, 2012, 120, 1553-1553.	1.4	2
46	Skip pattern approach toward the early access of innovative anticancer drugs. ESMO Open, 2021, 6, 100227.	4.5	1
47	Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy. Blood, 2016, 128, 4141-4141.	1.4	1
48	Analysis of T-Cell Receptor Beta-Constant Region Expression for Rapid Assessment of T-Cell Clonality. Blood, 2018, 132, 2867-2867.	1.4	1
49	DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA. Hematological Oncology, 2019, 37, 429-430.	1.7	0
50	Clinical Relevance of Vascular Endothelial Growth Factor In Myelodysplastic Syndromes. Blood, 2010, 116, 4030-4030.	1.4	0
51	Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-Cell Receptors. Blood, 2011, 118, 2847-2847.	1.4	0
52	Immune Thrombocytopenia Associated to Low-Dose Alemtuzumab Therapy in Chronic Lymphocytic Leukemia: A Single Retrospective Center Experience. Blood, 2012, 120, 4598-4598.	1.4	0
53	Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas. Blood, 2015, 126, 4503-4503.	1.4	0
54	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma. Blood, 2016, 128, 4161-4161.	1.4	0

GIUSEPPE GRITTI

#	Article	IF	CITATIONS
55	Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 3007-3007.	1.4	Ο
56	Clinical-Grade Transduction of Allogeneic Cytokine Induced Killer (CIK) Cells with CD19 Chimeric Antigen Receptor (CAR) Using Sleeping Beauty (SB) Transposon: Successful GMP-Compliant Manufacturing for Clinical Applications. Blood, 2018, 132, 196-196.	1.4	0
57	Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity. Blood, 2020, 136, 34-34.	1.4	Ο